key: cord-1015547-cxq3se5z
authors: Joergensen, T. S.; Blin, K.; Kuntke, F.; Salling, H. K.; Michaelsen, T. Y.; Albertsen, M.; Larsen, H.
title: A rapid, cost efficient and simple method to identify current SARS-CoV-2 variants of concern by Sanger sequencing part of the spike protein gene
date: 2021-03-29
journal: nan
DOI: 10.1101/2021.03.27.21252266
sha: b61a44117243be25ce7bf23174d176be8ec322de
doc_id: 1015547
cord_uid: cxq3se5z

In 2020, the novel coronavirus, SARS-CoV-2, caused a pandemic, which is still raging at the time of writing this. Many countries have set up high throughput RT-qPCR based diagnostics for people with COVID-19 symptoms and for the wider population. In addition, with the use of whole genome sequencing (WGS) new lineages of SARS-CoV-2 have been identified that have been associated with increased transmissibility or altered vaccine efficacy, so-called Variants of Concern (VoC). WGS is generally too labor intensive and expensive to be applied to all positive samples from the diagnostic tests, and often has a turnaround time too long to enable VoC focused contact tracing. Here, we propose to use Sanger sequencing for the detection of common variants of concern and key mutations in early 2021, using a single set of the recognized ARTIC Network primers. The proposed setup relies entirely on materials and methods already in use in diagnostic RT-qPCR labs and on existing infrastructure from companies that have specialized in cheap and rapid turnaround Sanger sequencing. In addition, we provide an automated mutation calling software (https://github.com/kblin/covid-spike-classification). We have validated the setup on 195 SARS-CoV-2 positive samples, and we were able to profile >85% of RT-qPCR positive samples, where the last 15% largely stem from samples with low viral count. At approximately 4 {euro} per sample in material cost, with minimal hands-on time, little data handling, and a turnaround time of less than 30 hours, the setup is simple enough to be implemented in any SARS-CoV-2 RT-qPCR diagnostic lab. Our protocol provides results that can be used to focus contact-tracing efforts and it is cheap enough for the tracking and surveillance of all positive samples for emerging variants such as B.1.1.7, B.1.351 and P.1 as of January 2021.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.27.21252266 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Suppl. Table. 3: GISAID references  22   23 Abstract 24

In 2020, the novel coronavirus, SARS-CoV-2, caused a pandemic, which is still raging at the 25 time of writing this. Many countries have set up high throughput RT-qPCR based diagnostics 26 for people with COVID-19 symptoms and for the wider population. In addition, with the use of 27 whole genome sequencing (WGS) new lineages of SARS-CoV-2 have been identified that 28 have been associated with increased transmissibility or altered vaccine efficacy, so-called 29

Variants of Concern (VoC). WGS is generally too labor intensive and expensive to be 30 applied to all positive samples from the diagnostic tests, and often has a turnaround time too 31 long to enable VoC focused contact tracing. Here, we propose to use Sanger sequencing for 32 the detection of common variants of concern and key mutations in early 2021, using a single 33 set of the recognized ARTIC Network primers. The proposed setup relies entirely on 34 materials and methods already in use in diagnostic RT-qPCR labs and on existing 35 infrastructure from companies that have specialized in cheap and rapid turnaround Sanger 36 sequencing. In addition, we provide an automated mutation calling software 37 (https://github.com/kblin/covid-spike-classification). We have validated the setup on 195 38 SARS-CoV-2 positive samples, and we were able to profile >85% of RT is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.27.21252266 doi: medRxiv preprint the purification of input RNA. RT-PCR were set up in 20μl RT-PCR reactions using 10μl One 99

Step PrimeScript III (Takara, Shimogyō-ku, Kyoto) used in the diagnostic SARS-CoV-2 test 100 facility at DTU, 0.4μM forward primer, 0.4μM reverse primer, and 2-5μl purified template 101 RNA per reaction ( Table 1 ). The RT-PCR reaction was performed (after the initial test of 102 annealing temperature) using the following program: reverse transcription for 5 min at 52 °C, 103 then hot start polymerase activation at 95 °C for 10s, followed by 45 cycles of 95 °C for 5s, 104 58 °C for 30 s, and 72 °C for 1 min, followed by 5 min at 72 °C. This protocol is in line with 105 the manufacturer's instruction for a PCR product length of approx. 1kb. The resulting PCR 106 products were analyzed using gel electrophoresis on a 1% agarose gel to confirm 107 amplification (Suppl. Fig. 1 ). Then 10μl PCR product was purified with 0.8x volume of SPRI is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.27.21252266 doi: medRxiv preprint P681H, P681R, I692V, A701V, T716I). Information is primarily derived from covariant.org 15 ), 127 and reported as a csv table file, along with the basecalls in fastq format. The program is 128 available from https://github.com/kblin/covid-spike-classification. Alternatively, Statens 129 Serum Institut (SSI), the Danish government body for SARS-CoV-2 surveillance, has set up 130 a self-contained web-app running the program without data upload at 131 https://ssi.biolib.com/app/covid-spike-classification/run. 132

The protocol for this method has been published at protocols.io at 133 dx.doi.org/10.17504/protocols.io.bsbdnai6 16 . 134

The input RNA from the diagnostic SARS-CoV-2 RT-qPCR facility was obtained from 135 oropharyngeal swabs with specimens placed immediately into a tube with 3M Guanidine 136

Thiocyanate for instant lysis of viral particles. This ensures stability of RNA during 137 transportation and during the process of transferring patient material from tube to plate. The 138

RT-qPCR kit is demonstrated on PCR applications and has a Limit of Detection of 1 copy/µL 139 for viral RNA (Centre for Diagnostics, DTU). RNA was purified in cooled racks and placed 140 directly into the fridge prior to RT-qPCR reaction set-up. Following the reaction set up, the 141 RNA was frozen at -20 C° prior to being thawed for sequencing within 1-2 days. For the 142 diagnostic SARS-CoV-2 test, two separate primer sets and probes target the SARS-CoV-2 143

Nucleoprotein gene (N1 and N2), and one internal positive control primer set and probe 144 which target the human RNAse P. A three-color multiplex probe system from Pentabase 145 (Odense, Denmark) was used. 146

To estimate the profiling potential of the spike gene amplicon, SARS-CoV-2 strain data was 147 collected from GISAID on 2021-01-29. Data was first pre-filtered by host "human" and 148 minimum length > 25000. The data were then further filtered by excluding cases older than 149 the first date at which all three VoCs appear (2020-12-04). This resulted in a dataset of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Classification of SARS-CoV-2 genomes is often performed using Nextclade 19 or Pangolin 18 189 which uses several lineage defining mutations, but only a subset of mutations is needed as 190 this allows profiling of incomplete genomes. Using 9 key amino-acid mutations included in a 191 single 1001 bp amplicon in the spike protein gene (Table 2) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.27.21252266 doi: medRxiv preprint and 30 minutes for preparation of samples for sequencing), along with the two hour and 40 213 minutes run-time for the RT-PCR per 96 well PCR plate. The workflows proposed here are 214 easy to automate. We estimate that the total price of these simple steps is 4€ per sample in 215 material cost including plastware, enzymes, buffers, shipping, and sequencing, making the 216 workflow cost efficient compared to WGS or multi-target RT-qPCR typing approaches. If 217 Sanger sequencing can be performed in-house the time to result can be less than six hours 218 from positive COVID-19 sample to variant call, which is faster than any high throughput 219 WGS based analysis, with less computational workload and data storage. 220

To evaluate the suitability of the Sanger sequencing method for mutation calling in the RT-221 PCR product, we initially used six SARS-CoV-2 positive RNA samples from the large scale 222 testing facility at DTU. We shipped both SPRI purified and unpurified RT-PCR products for 223

Sanger sequencing (Table 1 , Suppl Figure 1 ). In this way, we got two Sanger reads from 224 each of the 6 samples, which we used to verify that the mutations are called identically 225 regardless of purification status. Suppl. Table 1 shows an overview of the 12 Sanger reads. 226

We tested a custom made primer set with similar results (Suppl. Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.27.21252266 doi: medRxiv preprint gratefully to researchers, clinicians, and public health authorities for making SARS-CoV-2 307 sequence data available through GISAID (supplementary table 3) . 308 309 . CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.27.21252266 doi: medRxiv preprint

A new coronavirus associated with human respiratory disease in China. 312

Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 314 variants of concern

Analytical sensitivity and efficiency comparisons of SARS-CoV-2

RT-qPCR primer-probe sets

Quick, J. nCoV-2019 sequencing protocol v3 (LoCost)

Data, disease and diplomacy: GISAID's innovative 319 contribution to global health

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK 321 defined by a novel set of spike mutations

Genomic Epidemiology

characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-324 spike-mutations/563

Emergence and rapid spread of a new severe acute respiratory 326 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in 327

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary 329 findings -SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology

The effect of SARS-CoV-2 variant B.1.1.7 on symptomatology, re-333 infection and transmissibility

Comprehensive mapping of mutations to the SARS-CoV-2 336 receptor-binding domain that affect recognition by polyclonal human serum antibodies

DNA sequencing with chain-terminating 339 inhibitors

Tracy: basecalling, 341 alignment, assembly and deconvolution of sanger chromatogram trace files

Fast gapped-read alignment with Bowtie 2. Nat

The Sequence Alignment/Map format and SAMtools

CoVariants: SARS-CoV-2 Mutations and Variants of Interest

Sanger sequencing of a part of the SARS-CoV-2 spike protein

A dynamic nomenclature proposal for SARS-CoV-2 lineages to 352 assist genomic epidemiology

Nextstrain: real-time tracking of pathogen evolution

It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.27.21252266 doi: medRxiv preprint